<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INTERFERON GAMMA-1b</span><br/>(in-ter-feer'on)<br/><span class="topboxtradename">Actimmune<br/></span><b>Classifications:</b> <span class="classification"> immunomodulator</span>; <span class="classification">interferon</span><br/><b>Prototype: </b>Interferon alfa-2a<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mcg (2 million IU)/0.5 mL vial</p>
<h1><a name="action">Actions</a></h1>
<p>Has potent phagocyte-activating effects that include stimulating macrophages and generation of toxic oxygen metabolites (i.e.,
         free radicals) capable of destroying virally infected cells. It also exerts antitumor effects by increasing expression of
         tumor suppressor genes and activating macrophages to lyse tumor cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Is a naturally occurring cytokine with antiviral, immunomodulatory, and antiproliferative activity. It enhances phagocyte
         function in chronic granulomatous disease and improves killing of viruses; also enhances osteoclast function in malignant
         osteopetrosis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Chronic granulomatous disease, severe malignant osteopetrosis</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Idiopathic pulmonary fibrosis, refractory mycobacterium infection, ovarian cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to interferon gamma or products derived from <i>E. coli;</i> pregnancy (category C); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Preexisting cardiac disease; seizure disorders and compromised CNS function; myelosuppression. Safety and efficacy in children
         are unknown.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Granulomatous Disease, Osteopetrosis</span><br/><span class="rdage">Adult/Child:</span> <span class="rdroute">SC</span>
<i>BSA <img src="../images/special/greaterorequal.gif"/>0.5 m<sup>2</sup> 50 mcg/m<sup>2</sup>
</i> 3 times weekly<br/><span class="rdage">Adult/Child:</span> <span class="rdroute">SC</span>
<i>BSA <img src="../images/special/lesserorequal.gif"/>0.5 m<sup>2</sup> 1.5 mcg/kg</i> 3 times weekly<br/><br/><span class="indicationtitle">Idiopathic Pulmonary Fibrosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 180200 mcg 3 times weekly<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Pretreatment (4 h before) with acetaminophen is recommended to reduce headache, myalgia, and fever. Treatment should be continued
            24 h postinjection.
            			
         </li>
</ul><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Do not shake vial. Inject SC undiluted into right or left deltoid area or anterior thigh area</li>
<li>Avoid intradermal or IV injection. Rotate injection sites.</li>
<li>Store 2°8° C (36°46° F); do not freeze. Discard any unused portions or any vial left at room
            temperature for &gt;12 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fever, fatigue, chills,</span> myalgia, arthralgia, night sweats. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> altered mental status, ataxia, confusion, dizziness, Parkinsonian symptoms, disorientation, seizures, hallucinations. <span class="typehead">CV:</span> Heart block, heart failure, DVT, hypotension, <span class="speceff-life">MI</span>, syncope, tachyarrhythmia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea.</span>
<span class="typehead">Hematologic:</span>
<span class="speceff-common">Leukopenia, thrombocytopenia.</span>
<span class="typehead">Respiratory:</span> Bronchospasm, interstitial pneumonitis, pulmonary embolism, tachypnea. <span class="typehead">Skin:</span> Local skin necrosis at injection site, <span class="speceff-common">pain at injection site, rash.</span>
<span class="typehead">Urogenital:</span> Reversible renal insufficiency.  
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Use cautiously with <b>amiophylline, fosphenytoin, phenytoin, theophylline, warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% absorbed from SC site. <span class="typehead">Peak:</span> 7 h <span class="typehead">Half-Life:</span> 5.9 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor CV status frequently. Report promptly severe hypotension and/or syncope.</li>
<li>Monitor for and report S&amp;S of infection.</li>
<li>Lab tests: Baseline and at 3 mo CBC with differential and platelet counts; complete blood chemistry (including renal and liver
            function tests), and urinalysis.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly: skin rash, itching, unusual weakness or tiredness, chest pain or palpitations, or signs of an infection.</li>
<li>Do not accept vaccination with a live vaccine during or for 3 mo following the end of therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>